Vivos Therapeutics Inc. reported a 22% year-over-year increase in revenue for the second quarter of 2026, citing strong demand for its sleep apnea treatment systems. The company’s Q2 2026 revenue totaled $12.4 million, up from $10.2 million in the same period last year.
Revenue growth was primarily attributed to higher unit sales of Vivos’ proprietary oral appliance systems, which target mild to moderate obstructive sleep apnea. The company also highlighted expansion in its commercial partnerships and increased market penetration in the U.S. and international markets.
Gross profit for the quarter rose 18% to $8.1 million, while net income reached $1.9 million, compared with a net loss of $400,000 in Q2 2025. Vivos attributed the improved profitability to operational efficiencies and cost controls implemented during the year.
Cash and cash equivalents at the end of the quarter stood at $15.3 million, providing a liquidity cushion for ongoing research and development initiatives. The company did not revise its full-year 2026 guidance, reaffirming its revenue target of $50 million to $52 million.
Vivos Therapeutics’ stock has gained approximately 12% year-to-date, outperforming the broader healthcare sector, which has risen 5% over the same period.
